The Fatal Brew: a Comprehensive Study on Deadly Potions

The Elixir Sulfanilamide Disaster: How a Children’s Medicine Rewrote American Drug Law

In the annals of public health history, few events carry the weight of the Elixir Sulfanilamide disaster of 1937. At a time when pharmaceutical companies operated with minimal government oversight, a single product decision made in a Tennessee laboratory would kill more than a hundred Americans, most of them children, and fundamentally reshape the relationship between the federal government and the drug industry. The story of Elixir Sulfanilamide is not simply a cautionary tale about negligence. It is a window into a regulatory vacuum that existed for decades, and a testament to how tragedy can become the unlikely architect of lasting reform.

The World Before Pharmaceutical Regulation

To understand why the Elixir Sulfanilamide disaster was possible, it is necessary to understand the regulatory landscape that preceded it. In the late nineteenth and early twentieth centuries, the American marketplace was flooded with patent medicines and tonics that made extraordinary claims with little to no scientific basis. Products containing alcohol, cocaine, opium, and other dangerous substances were sold openly, often marketed toward women and children as remedies for everything from fatigue to tuberculosis.

The Pure Food and Drug Act of 1906 represented the first significant federal attempt to address this chaos, largely driven by public outrage following the publication of Upton Sinclair’s novel The Jungle, which exposed horrifying conditions in the meatpacking industry. However, the 1906 act was limited in scope. It prohibited the sale of adulterated or misbranded foods and drugs, but it did not require manufacturers to prove that their products were safe before bringing them to market. The burden of proof fell on the government to demonstrate that a product was harmful after the fact, a nearly impossible standard to meet in a timely way. Manufacturers could essentially sell whatever they wished, provided they did not make overtly fraudulent label claims. This left an enormous and dangerous gap in consumer protection that would persist for more than three decades.

Development and Distribution of a Deadly Medicine

Against this backdrop, the S.E. Massengill Company of Bristol, Tennessee, set out in 1937 to develop a liquid formulation of sulfanilamide, one of the earliest antibiotic drugs. Sulfanilamide had proven remarkably effective against streptococcal infections and was widely celebrated in medical circles as a near-miraculous treatment. The drug was already available in tablet and powder forms, but the company recognized a commercial opportunity to produce a version that children could more easily consume. Tablets and capsules were difficult for young patients to swallow, and a pleasant-tasting liquid solution seemed like a practical and profitable solution.

The task of developing this formulation fell to Harold Watkins, the company’s chief chemist. Watkins experimented with various solvents and eventually settled on diethylene glycol, a chemical compound related to antifreeze. Diethylene glycol dissolved sulfanilamide effectively and imparted a naturally sweet taste, making the resulting liquid palatable. Watkins added raspberry flavoring and saccharin to further improve the flavor, and the product was deemed ready for market. Crucially, no toxicity testing was conducted on the solvent or the final formulation. Watkins and the company were either unaware of or indifferent to the fact that diethylene glycol had been identified as toxic in scientific literature as early as the 1930s. The Massengill Company distributed approximately 240 gallons of the elixir across the United States before any alarm was raised.

The deaths began accumulating in October 1937. Physicians in Tulsa, Oklahoma, were among the first to notice a cluster of patients, predominantly children, presenting with severe kidney failure after taking the new liquid sulfanilamide preparation. The symptoms were agonizing. Patients experienced intense abdominal pain, cessation of urination, nausea, and convulsions before dying. A Tulsa physician named James Stevenson contacted the American Medical Association to report his suspicions, and the organization quickly moved to alert the broader medical community. The Food and Drug Administration, which at the time employed only around 300 inspectors and scientists, launched a frantic nationwide effort to recall the product. Agents fanned out across the country to recover every bottle they could locate. By the time the recall was complete, 107 people had died, the majority of them children.

Public Outcry and the Limits of Existing Law

The public reaction to the deaths was one of grief and fury. Newspapers across the country ran stories about the victims, many of them accompanied by photographs of young children who had died after taking medicine their parents believed would help them recover from routine illnesses. Frances Kelsey, who would later become famous for blocking the approval of thalidomide in the United States, was a young pharmacologist at the time and was among those who studied the disaster closely. The human cost was undeniable and deeply felt.

What made the public outrage even more potent was the discovery of how little legal recourse existed. When the FDA moved to prosecute the Massengill Company, it found that the firm had not actually violated the 1906 Pure Food and Drug Act in any meaningful way. The law did not require safety testing. The only charge that could be brought against Massengill was that the product had been mislabeled, because the word "elixir" technically referred to an alcohol-based solution, and diethylene glycol is not an alcohol. The company was fined the maximum allowable amount for that charge, which was a few thousand dollars. Harold Watkins, the chemist responsible for the formulation, died by suicide before the case was fully resolved, reportedly devastated by the consequences of his work. Samuel Massengill, the company’s owner, expressed little public remorse, stating that he had done nothing illegal and that he could not have known the solvent was dangerous.

This grotesque inadequacy of the law became the central argument for sweeping legislative reform. Frances Oldham, members of Congress, and public health advocates used the disaster to demonstrate that the existing regulatory framework was fundamentally broken. The government could only act after people had already died, and even then, its punitive powers were negligible.

The Federal Food, Drug, and Cosmetic Act of 1938

President Franklin D. Roosevelt signed the Federal Food, Drug, and Cosmetic Act into law in June 1938, less than a year after the Elixir Sulfanilamide deaths. The legislation represented a dramatic expansion of federal authority over the pharmaceutical industry and addressed nearly every weakness that the disaster had exposed. Most significantly, the act required manufacturers to submit evidence of a drug’s safety to the FDA before it could be approved for sale. The burden of proof was reversed. Companies could no longer simply release a product and wait for harm to occur. They were now legally obligated to demonstrate safety in advance.

The act also gave the FDA authority to inspect manufacturing facilities, established standards for food quality and labeling, and extended federal oversight to cosmetics for the first time. It created a formal new drug application process that became the foundation of the modern drug approval system. While the act did not yet require proof of efficacy, meaning companies still did not have to show that their drugs actually worked, only that they were not acutely harmful, it represented an enormous step forward from the near-total absence of pre-market scrutiny that had existed before.

The 1938 act would later be strengthened further, most notably by the Kefauver-Harris Amendment of 1962, which was itself prompted by another near-disaster involving thalidomide. That amendment added the requirement that drugs demonstrate both effectiveness and safety. But the essential framework, the idea that the government has both the authority and the responsibility to evaluate new drugs before they reach consumers, was born directly from the Elixir Sulfanilamide tragedy.

Conclusion

The Elixir Sulfanilamide disaster occupies a peculiar place in history. It is not well remembered outside public health circles, yet its consequences are felt by everyone who has ever had a prescription filled at a pharmacy or purchased an over-the-counter medication with confidence in its safety. The more than one hundred people who died in 1937, most of them children seeking relief from ordinary illness, did not die for nothing. Their deaths exposed a system that was dangerously inadequate and forced a nation to confront the consequences of treating public health as a secondary concern to commercial freedom.

The lesson of Elixir Sulfanilamide is not simply that chemicals should be tested before they are given to children, though that lesson is obvious enough. The deeper lesson is that regulatory frameworks do not emerge from abstract principles alone. They are built, often painfully and slowly, from the accumulated evidence of what happens when they do not exist. Every drug safety requirement that exists today carries within it the memory of a harm that made that requirement necessary. In that sense, the children who died in 1937 remain, in a quiet and largely unacknowledged way, among the most consequential figures in the history of American medicine.